8-K: Establishment Labs Reports Strong US Motiva Sales, Targets Q4 2025 FDA Reconstruction Filing and 2026 Preserv Launch

Establishment Labs Holdings Inc. announced robust US sales for its Motiva implants, exceeding 1,000 offering surgeons, and outlined plans for a Q4 2025 US FDA reconstruction filing and a 2026 US launch for Preserv, alongside positive financial guidance for 2025.

Summary

• Establishment Labs Holdings Inc. hosted an analyst and investor event on June 12, 2025, providing updates on its Motiva product line and future strategic initiatives.
• Over 1,000 surgeons in the United States now offer Motiva implants, demonstrating significant market penetration.
• The company expects Motiva sales in the United States to reach approximately $9.5 million to $10 million in the second quarter of fiscal 2025, building on Q1 sales of $6.2 million.
• Establishment Labs anticipates filing for US FDA approval of Motiva Implants for use in reconstruction by the fourth quarter of 2025.
• The US launch of Preserv, a breast tissue preservation product, is projected for the first half of 2026.
• The company reaffirmed its 2025 revenue guidance of $205 million to $210 million, with US revenue expected to meaningfully exceed $35 million.
• Gross margins are expected to increase by 200-300 basis points, primarily driven by US operations.
• Operating expenses outside the US and corporate expenses have been reduced by approximately 30% from 2023 levels.
• Establishment Labs expects to achieve EBITDA positive status in 2025 and become cash flow positive in 2026.
• The company aims for over 20% growth for at least the next three years.
• Preliminary 5-year data from the Motiva U.S. IDE Study shows low complication rates: 0.5% for capsular contracture (Baker Grade III/IV) and 0.6% for suspected or confirmed rupture.
• The Motiva Flora Tissue Expander demonstrated significantly lower infection/cellulitis rates (1.9% vs. 6.2%) and a trend toward lower seroma rates (1.9% vs. 6.4%) compared to traditional tissue expanders in a recent study.
• The company is developing a Minimally Invasive Platform, with tools filed with the FDA in early June, and early experience expected in Q3 2025.
• Mia Femtech Study clinical outcomes through 3 years show 0.0% for capsular contracture, rupture, infection, seroma, hematoma, and rippling, with only 1.0% for malposition/displacement and any reoperation.
• The company is exploring new markets, including gluteal enhancement with GEM (Gluteal Ergonomic Modeling) and addressing the evolving needs of patients undergoing GLP-1 induced weight loss.

Sentiment

Score: 9

Explanation: The document conveys an overwhelmingly positive outlook, highlighting strong sales growth, significant market penetration, favorable clinical data, clear paths to profitability (EBITDA and cash flow positive), and a robust innovation pipeline. Management comments and surgeon testimonials reinforce the superior product performance and market disruption potential. The strategic focus on emerging trends like GLP-1 patient needs further strengthens the positive sentiment.

Positives

• Strong US market penetration with over 1,000 surgeons now offering Motiva implants.
• Robust expected US Motiva sales of $9.5 million to $10 million in Q2 2025, indicating significant growth.
• Positive 2025 revenue guidance of $205 million to $210 million, with US revenue expected to meaningfully exceed $35 million.
• Anticipated gross margin expansion of 200-300 basis points, driven by US market performance.
• Significant reduction in OUS and corporate operating expenses by approximately 30% from 2023.
• Expectation to achieve EBITDA positive status in 2025 and cash flow positive in 2026, indicating improving financial health.
• Projected growth rate of over 20% for at least the next three years, signaling strong future prospects.
• Low complication rates reported in the preliminary 5-year Motiva U.S. IDE Study, including 0.5% capsular contracture and 0.6% rupture.
• Motiva Flora Tissue Expander shows superior clinical outcomes with lower infection and seroma rates compared to traditional expanders, and is MRI conditional.
• Mia Femtech Study demonstrates exceptionally low complication rates (0.0% for most complications) through 3 years, highlighting product safety and efficacy.
• Successful Meghan Trainor influencer campaign generated 4.8 billion impressions, 1.7 million video views, and over 3,400 leads, leading to 700+ surgeries.
• High patient preference for Motiva implants (93%) over other brands, as reported by a panel surgeon.
• Innovation pipeline includes Minimally Invasive Tools and GEM for gluteal enhancement, expanding market opportunities.
• Strategic positioning to address the aesthetic needs of patients undergoing GLP-1 induced weight loss, opening a new patient demographic.

Risks

• Forward-looking statements are based on current expectations and information, which may be limited or incomplete, and actual outcomes may differ materially.
• Preliminary financial data has not been audited, reviewed, or compiled by independent accounting firms, and undue reliance should not be placed on it.
• Ability to successfully, timely, and cost-effectively develop, seek, and obtain regulatory clearance for and commercialize product offerings.
• The rate of adoption of products by healthcare providers or other customers may not meet expectations.
• The success of marketing initiatives and the safe and effective use of products are crucial for market penetration.
• Ability to protect intellectual property and expand upon and/or secure sources of credit or capital.
• Reliance on qualified suppliers to avoid significant interruptions in supply chains.
• Ability to attract and retain key personnel and scale operations to meet market demands.
• The effect on the business of existing and new regulatory requirements.
• Other economic and competitive factors, including those set forth in SEC filings, could impact results.

Future Outlook

Establishment Labs anticipates continued strong growth, projecting over 20% growth for at least the next three years. The company expects to achieve EBITDA positive status in 2025 and become cash flow positive in 2026. Key product launches include the US FDA filing for Motiva Implants in reconstruction by Q4 2025 and the US launch of Preserv in the first half of 2026. The company is also expanding its minimally invasive platform and exploring new markets like gluteal enhancement and addressing the aesthetic needs of GLP-1 weight loss patients.

Management Comments

• "Over 1,000 surgeons now offer Motiva implants in the United States."
• "We expect approximately $9.5 million to $10 million in Motiva sales in the United States in the second quarter of fiscal 2025."
• "We expect to file for US FDA approval of Motiva Implants for use in reconstruction in the fourth quarter of 2025."
• "The launch of Preserv in the United States is expected in the first half of 2026."
• "Motiva technology is superior as compared to competitive devices and has created two new markets utilizing minimally invasive technology (Mia and Preserve)." Dr. Mark Epstein
• "Motiva implants feel more natural, ripple less, and have very rare capsular contracture. I have not seen a single rupture." Dr. Nolan Karp
• "When the Motiva implants are approved [for reconstruction] we will switch at my institution immediately, and I expect most other institutions will switch as well." Dr. Nolan Karp
• "The Motiva Flora SmoothSilk Tissue Expander may contribute to improved clinical outcomes with fewer surgical interventions and enhanced precision in radiation treatment planning." Dr. Dennis Hammond
• "The 'Ozempification of Aesthetics' presents new challenges and opportunities for plastic surgery, with evolving patient needs for skin laxity and volume issues." Dr. Johnny Franco

Industry Context

The announcement highlights Establishment Labs' strong position in the breast aesthetics and reconstruction market, driven by innovative products like Motiva and its minimally invasive platform. The company is strategically addressing emerging trends, such as the 'Ozempification of Aesthetics,' which refers to the increasing number of patients seeking aesthetic procedures due to weight loss from GLP-1 medications. This trend creates new opportunities for plastic surgeons to address skin laxity and volume loss, areas where Establishment Labs' products, particularly those designed for tissue preservation and minimally invasive techniques, can offer solutions. The focus on reconstruction also aligns with a significant and growing segment of the breast surgery market, especially with the demonstrated benefits of Motiva Flora.

Comparison to Industry Standards

• Motiva U.S. IDE Study 5-year preliminary data shows a capsular contracture rate of 0.5% (Baker Grade III/IV) and rupture rate of 0.6%, which are notably low compared to historical rates for breast implants from competitors like Mentor and Allergan.
• The Motiva Flora Tissue Expander demonstrated significantly lower infection/cellulitis rates (1.9% vs. 6.2%) and a trend toward lower seroma rates (1.9% vs. 6.4%) compared to Traditional Tissue Expanders (TTEs) from Mentor and Allergan in a study involving 867 patients.
• Motiva Flora is highlighted as the only MRI Conditional Expander in the market, allowing for imaging during expansion and more targeted radiation protocols, a distinct advantage over non-MRI conditional devices from competitors.
• In cases requiring MRI, 0/3 patients with Motiva Flora required explantation, whereas 6/6 patients with TTEs (Mentor & Allergan) required prior device removal, showcasing superior MRI compatibility.
• Surgeon testimonials indicate a 93% patient preference for Motiva implants over other brands, suggesting a strong competitive advantage in patient satisfaction and natural feel.
• Motiva implants are described as allowing for prepectoral breast augmentation in women with very thin tissue and creating narrower cleavage, offering advantages over traditional subpectoral approaches often associated with other implant types.
• The company's focus on 'SmoothSilk' surface technology and 'TrueMonobloc' shell is presented as superior to competitive devices, contributing to lower complication rates like capsular contracture and rippling.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong sales growth, clear path to profitability (EBITDA and cash flow positive), expanding market opportunities, and positive financial guidance, potentially leading to increased share value.
• **Patients**: Positive impact through access to innovative breast implants and tissue expanders with demonstrated low complication rates, natural feel, and advanced features like MRI compatibility, potentially leading to better aesthetic and reconstructive outcomes.
• **Surgeons**: Positive impact through access to advanced products (Motiva, Flora, Mia, Preserv, GEM) that offer superior clinical outcomes, ease of use (Motiva Portal), and opportunities to expand their practice to new patient demographics (e.g., GLP-1 patients).
• **Employees**: Potential positive impact from company growth and expansion, possibly leading to job security and opportunities, particularly in the US commercial operations.
• **Creditors**: Positive impact from improved financial health, profitability, and cash flow generation, reducing credit risk.

Next Steps

• Continue staffing the U.S. organization with plastic surgery experienced talent.
• Build out a seamless, easy-to-navigate customer ordering platform and overall operating system.
• Build sufficient inventory and place permanent consignments in 200 targeted accounts.
• Focus execution on surgeon training and engagement and driving overall brand awareness.
• File for US FDA approval of Motiva Implants for use in reconstruction in the fourth quarter of 2025.
• Begin early experience with Minimally Invasive Tools in the third quarter of 2025.
• Launch Preserv in the United States in the first half of 2026.
• Continue to drive efficiencies in OPEX and leverage stable OPEX in outer quarters.
• Scale up Preserv Mia and GEM PMA Supplements.
• Continue development of new technology, including the Zen Technology Platform.

Key Dates

Recommendation

Keywords

Breast implants, Motiva, Establishment Labs, Plastic surgery, Aesthetic medicine, Breast augmentation, Breast reconstruction, FDA approval, Medical devices, GLP-1, Mia Femtech, Preserv, Corporate earnings, Financial guidance, EBITDA, Cash flow, Minimally invasive surgery